



No. at risk							
VKA	732	713	645	528	435	335	224
Dabigatran	638	624	569	483	417	323	208
Apixaban	932	912	812	693	587	446	233
Rivaroxaban	591	577	543	474	402	320	169
Edoxaban	135	129	103	76	38	24	17

Supplementary Figure 1. Kaplan-Meier curve free from persistence in the maintenance group (60 days before enrollment). VAK, vitamin K antagonist.